Zobrazeno 1 - 10
of 327 568
pro vyhledávání: '"Aged"'
Autor:
Scriney, Aideen1 (AUTHOR) aideen.scriney2@mail.dcu.ie, Russell, Amy1 (AUTHOR), Loughney, Lisa2 (AUTHOR), Gallagher, Pamela1 (AUTHOR), Boran, Lorraine1 (AUTHOR)
Publikováno v:
Psycho-Oncology. Dec2022, Vol. 31 Issue 12, p2050-2062. 13p. 1 Diagram, 4 Charts.
Resilience in middle-aged partners of patients diagnosed with incurable cancer: A thematic analysis.
Autor:
Opsomer, Sophie1,2 Sophie.opsomer@kuleuven.be, Pype, Peter2,3, Lauwerier, Emelien2,4, De Lepeleire, Jan1
Publikováno v:
PLoS ONE. 8/14/2019, Vol. 14 Issue 8, p1-26. 26p.
Autor:
Vear, Natalie K.1 (AUTHOR) n.vear@uq.edu.au, Goodman, William1,2 (AUTHOR) w.goodman@uq.edu.au, Rose, Grace L.1,3 (AUTHOR) grose1@usc.edu.au, McCarthy, Alexandra L.1,4 (AUTHOR) s.mccarthy@uq.edu.au
Publikováno v:
Maturitas. Sep2023, Vol. 175, pN.PAG-N.PAG. 1p.
Publikováno v:
Clinical Oncology Week; 2024, p389-389, 1p
Publikováno v:
Women's Health Weekly; 7/2/2024, p630-630, 1p
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Virginia Paton, Gracie Lieberman, Melody A. Cobleigh, Debasish Tripathy, Nicholas J. Robert, Charles L. Vogel, Louis Fehrenbacher, Janet M. Wolter, Steven Shak, Susy Scholl, Dennis J. Slamon
Publikováno v:
Journal of Clinical Oncology. 41:1501-1510
PURPOSE Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody as a single agent was evalu